[go: up one dir, main page]

MA47970B1 - Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée - Google Patents

Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée

Info

Publication number
MA47970B1
MA47970B1 MA47970A MA47970A MA47970B1 MA 47970 B1 MA47970 B1 MA 47970B1 MA 47970 A MA47970 A MA 47970A MA 47970 A MA47970 A MA 47970A MA 47970 B1 MA47970 B1 MA 47970B1
Authority
MA
Morocco
Prior art keywords
jak inhibitor
compound
imidazo
inhibitor compound
piperidine
Prior art date
Application number
MA47970A
Other languages
English (en)
Inventor
Marta Dabros
Paul R Fatheree
Lan Jiang
Robert Murray Mckinnell
Venkat R Thalladi
Hao Zhang
Jerry Nzerem
Noah Benjamin
Melanie A Kleinschek
Glenn D Crater
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MA47970B1 publication Critical patent/MA47970B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un composé de formule 1 ou un sel pharmaceutiquement acceptable de celui-ci, qui est utile en tant qu'inhibiteur de jak. L'invention concerne également des formes cristallines du composé, des compositions pharmaceutiques comprenant le composé, des procédés d'utilisation de ce dernier pour traiter des maladies sensibles à un inhibiteur de jak, et des procédés ainsi que des intermédiaires utiles pour préparer ledit composé.
MA47970A 2017-05-01 2018-04-30 Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée MA47970B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492574P 2017-05-01 2017-05-01
PCT/US2018/030148 WO2018204238A1 (fr) 2017-05-01 2018-04-30 Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée

Publications (1)

Publication Number Publication Date
MA47970B1 true MA47970B1 (fr) 2022-03-31

Family

ID=62165730

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47970A MA47970B1 (fr) 2017-05-01 2018-04-30 Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée

Country Status (32)

Country Link
US (3) US10493077B2 (fr)
EP (1) EP3601283B1 (fr)
JP (1) JP7098656B2 (fr)
KR (1) KR102550225B1 (fr)
CN (1) CN110573508B (fr)
AR (1) AR111495A1 (fr)
AU (1) AU2018261593B2 (fr)
BR (1) BR112019022648A2 (fr)
CA (1) CA3056283A1 (fr)
CL (1) CL2019003086A1 (fr)
CO (1) CO2019011809A2 (fr)
CY (1) CY1125051T1 (fr)
DK (1) DK3601283T3 (fr)
EA (1) EA201992601A1 (fr)
ES (1) ES2908756T3 (fr)
HR (1) HRP20220330T1 (fr)
IL (1) IL270231B2 (fr)
LT (1) LT3601283T (fr)
MA (1) MA47970B1 (fr)
MD (1) MD3601283T2 (fr)
MX (1) MX388751B (fr)
NZ (1) NZ757570A (fr)
PH (1) PH12019502264A1 (fr)
PL (1) PL3601283T3 (fr)
PT (1) PT3601283T (fr)
RS (1) RS62995B1 (fr)
SG (1) SG11201908604YA (fr)
SI (1) SI3601283T1 (fr)
SM (1) SMT202200079T1 (fr)
TW (1) TWI760486B (fr)
UA (1) UA124478C2 (fr)
WO (1) WO2018204238A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
JP7134990B2 (ja) 2017-03-09 2022-09-12 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 縮合イミダゾ－ピペリジンｊａｋ阻害剤
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
MX388748B (es) 2017-05-01 2025-03-20 Theravance Biopharma R&D Ip Llc Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
AR116116A1 (es) 2018-09-04 2021-03-31 Theravance Biopharma R&D Ip Llc Proceso para elaborar inhibidores de jak e intermediarios de los mismos
AU2019335200A1 (en) 2018-09-04 2021-03-11 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
KR102826491B1 (ko) 2018-09-04 2025-06-27 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 디메틸 아미노 아제티딘 아마이드
AU2019373059A1 (en) 2018-10-29 2021-05-06 Theravance Biopharma R&D Ip, Llc 2-azabicyclo hexane compound as JAK inhibitor
JP7680955B2 (ja) 2019-01-11 2025-05-21 ネイジス ファーマシューティカルズ インコーポレイテッド ロイコトリエン合成阻害剤
CN111606908B (zh) 2019-02-25 2021-08-24 河南迈英诺医药科技有限公司 Jak抑制剂化合物及其用途
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN115244047A (zh) * 2020-03-18 2022-10-25 四川海思科制药有限公司 一种吲唑衍生物及其在医药上的应用
CN111620868B (zh) * 2020-05-28 2021-08-31 爱斯特（成都）生物制药股份有限公司 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法
JP2024524214A (ja) * 2021-06-25 2024-07-05 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としてのイミダゾロインダゾール化合物
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (fr) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2532800C (fr) 2003-07-23 2013-06-18 Exelixis, Inc. Modulateurs de la proteine alk (anaplastic lymphoma kinase) et leurs methodes d'utilisation
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
WO2010114971A1 (fr) 2009-04-03 2010-10-07 Sepracor Inc. Composés utilisables pour le traitement de troubles à médiation par le récepteur métabotropique 5 au glutamate et leurs procédés d'utilisation
SI3001903T1 (en) 2009-12-21 2018-02-28 Samumed, Llc 1h-pyrazolo(3,4-b)pyridines and therapeutic uses thereof
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
ES2654051T3 (es) 2013-12-05 2018-02-12 Pfizer Inc. Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
GEP20186921B (en) 2014-05-14 2018-11-12 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (fr) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Composés hétérocycliques utilisés comme inhibiteurs de erk
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
PL3371185T3 (pl) 2015-11-03 2021-04-06 Topivert Pharma Limited Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
US10851097B2 (en) 2015-11-03 2020-12-01 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
JP7134990B2 (ja) 2017-03-09 2022-09-12 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 縮合イミダゾ－ピペリジンｊａｋ阻害剤
WO2018204236A1 (fr) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Formes cristallines d'un composé inhibiteur de jak
MX388748B (es) 2017-05-01 2025-03-20 Theravance Biopharma R&D Ip Llc Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak

Also Published As

Publication number Publication date
CO2019011809A2 (es) 2020-01-17
RS62995B1 (sr) 2022-03-31
MX2019012942A (es) 2019-12-16
SG11201908604YA (en) 2019-10-30
ES2908756T3 (es) 2022-05-03
KR20190142389A (ko) 2019-12-26
HRP20220330T1 (hr) 2022-05-13
DK3601283T3 (da) 2022-04-04
IL270231B1 (en) 2023-04-01
SI3601283T1 (sl) 2022-04-29
CY1125051T1 (el) 2024-02-16
AR111495A1 (es) 2019-07-17
TW201841914A (zh) 2018-12-01
SMT202200079T1 (it) 2022-03-21
JP2020518581A (ja) 2020-06-25
KR102550225B1 (ko) 2023-07-03
JP7098656B2 (ja) 2022-07-11
CN110573508A (zh) 2019-12-13
WO2018204238A1 (fr) 2018-11-08
AU2018261593A1 (en) 2019-10-17
BR112019022648A2 (pt) 2020-05-19
EP3601283B1 (fr) 2021-12-29
NZ757570A (en) 2021-07-30
US10493077B2 (en) 2019-12-03
US20180311255A1 (en) 2018-11-01
PT3601283T (pt) 2022-02-10
US11160810B2 (en) 2021-11-02
CL2019003086A1 (es) 2020-01-24
CA3056283A1 (fr) 2018-11-08
MX388751B (es) 2025-03-20
PH12019502264A1 (en) 2020-09-21
EP3601283A1 (fr) 2020-02-05
US20200046719A1 (en) 2020-02-13
US20220008428A1 (en) 2022-01-13
IL270231A (fr) 2019-12-31
PL3601283T3 (pl) 2022-05-02
UA124478C2 (uk) 2021-09-22
MD3601283T2 (ro) 2022-05-31
TWI760486B (zh) 2022-04-11
LT3601283T (lt) 2022-02-25
AU2018261593B2 (en) 2021-08-26
IL270231B2 (en) 2023-08-01
EA201992601A1 (ru) 2020-03-03
CN110573508B (zh) 2022-07-05

Similar Documents

Publication Publication Date Title
MA47970B1 (fr) Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
CR20220251A (es) Nuevos derivados de metilquinazolinona
MA51620B1 (fr) Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
MA41256B1 (fr) Dosage spécifique de site d'un inhibiteur de btk
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
EA202191188A1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
CL2021002165A1 (es) Nuevos derivados de compuestos heterociclicos y uso de los mismos
MA55193B1 (fr) Procédés de préparation d'un inhibiteur de pi3k
AU2018277520A1 (en) 6-5 fused rings as C5a inhibitors
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA201692300A1 (ru) Производные карбоксамида
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MX2021007258A (es) Composiciones de esparsentan amorfas.
TN2016000491A1 (en) Carboxamide derivatives.